01 April 2026
01 April 2026
Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton.
Innovative diagnostics may reduce ~9-year diagnosis delay, but systemic barriers to implementation remain.
This acquisition will add Syfovre and Empaveli to Biogen’s portfolio of medicines.
Phase II CADENCE results position sotatercept as a potential first targeted therapy for CpcPH-HFpEF,.
At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, comparing single versus monthly dosing on blood pressure and a key biomarker.
Pending IND clearance, Telomir aims to start a Phase I/II clinical trial with Telomir-1 as oral treatment.
Symeres will assess Ambagon’s molecular glues through in vitro assays and mechanistic studies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
